公开(公告)号：EP1557431B1

公开(公告)日：2012-08-15

申请号：EP05007745.2

申请日：1997-03-04

申请人： SCIOS INC.

发明人： Mischak, Ronald P. ,  Lim, Garret A. ,  Scardina, Jan Marian

IPC分类号： C07K16/26 ,  G01N33/577 ,  C07K14/58

CPC分类号： C07K14/58 ,  C07K16/26 ,  C07K2317/34 ,  Y10S530/839 ,  Y10S530/841

公开(公告)号：EP2292662A2

公开(公告)日：2011-03-09

申请号：EP10013178.8

申请日：1997-03-04

申请人： SCIOS INC.

发明人： Mischak, Ronald P. ,  Lim, Garret A. ,  Scardina, Jan Marian

IPC分类号： C07K16/26 ,  G01N33/577 ,  C07K14/58

CPC分类号： C07K14/58 ,  C07K16/26 ,  C07K2317/34 ,  Y10S530/839 ,  Y10S530/841

摘要： The invention relates to an in vitro method of diagnosing congestive heart disease by quantifying hBNP in a sample. The method comprises: contacting a sample of the biological fluid with a first antibody, wherein the first antibody is monospecifically reactive to an hBNP fragment; forming a complex comprising hBNP in the biological fluid, the first antibody and a second antibody, wherein the second antibody is immunoreactive with hBNP or the first antibody, and wherein the second antibody comprises a label; and determining the amount of hBNP in the sample by quantifying the label in the complex.

摘要翻译： 本发明涉及通过定量样品中的hBNP来诊断充血性心脏病的体外方法。 该方法包括：使生物流体的样品与第一抗体接触，其中第一抗体与hBNP片段具有一体反应性; 在所述生物流体中形成包含hBNP的复合物，所述第一抗体和第二抗体，其中所述第二抗体与hBNP或所述第一抗体具有免疫反应性，并且其中所述第二抗体包含标记物; 并通过量化复合物中的标记来确定样品中hBNP的量。

公开(公告)号：EP1608631A4

公开(公告)日：2008-08-20

申请号：EP04758392

申请日：2004-03-26

申请人： SCIOS INC

发明人： DUGAR SUNDEEP ,  CHAKRAVARTY SARVAJIT ,  CONTE AURELIA ,  AXON JONATHAN ,  MCENROE GLENN

IPC分类号： C07D239/70 ,  A61K31/517 ,  A61K31/519 ,  C07D239/94 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D413/04 ,  C07D471/04 ,  C07D487/02 ,  C07D487/04 ,  C07D491/02 ,  C07D491/04 ,  C07D491/048 ,  C07D493/04 ,  C07D495/04 ,  C07D498/02 ,  C07D498/04

CPC分类号： C07D487/04 ,  A61K31/517 ,  C07D239/94 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D413/14 ,  C07D471/04 ,  C07D491/04 ,  C07D493/04 ,  C07D495/04 ,  C07D498/04

公开(公告)号：EP1714972A3

公开(公告)日：2008-05-28

申请号：EP06008034.8

申请日：1999-07-08

申请人： Scios, Inc.

发明人： Pollitt, N. Stephen ,  Buckley, Douglas I. ,  Stathis, Peter A. ,  Hartman, Taymar E. ,  Zhong, Ziyang

IPC分类号： C12N15/12 ,  C12N15/62 ,  C07K1/18 ,  C07K1/12

CPC分类号： C07K1/36 ,  C07K1/122 ,  C07K14/58 ,  C07K2319/00 ,  C07K2319/35 ,  C07K2319/75 ,  C12N9/1033 ,  C12N15/62 ,  C12P21/06 ,  C12Y203/01028

摘要： A method is described for producing a peptide having a pI above 8 or below 5 wherein the peptide is expressed as a fusion protein in which it is linked to a fusion partner through an acid cleavage site. The peptide is released from the fusion partner by acid cleavage in the absence of chaotrope. The fusion partner and its acid cleavage products, if any, have a net charge sufficiently different from that of the desired peptide to allow isolation of the peptide by ion-exchange chromatography.

公开(公告)号：EP1714972A2

公开(公告)日：2006-10-25

申请号：EP06008034.8

申请日：1999-07-08

申请人： Scios, Inc.

发明人： Pollitt, N. Stephen ,  Buckley, Douglas I. ,  Stathis, Peter A. ,  Hartman, Taymar E. ,  Zhong, Ziyang

IPC分类号： C07K1/12 ,  C07K14/58 ,  C12N15/62 ,  C12P21/06 ,  C12N9/10

CPC分类号： C07K1/36 ,  C07K1/122 ,  C07K14/58 ,  C07K2319/00 ,  C07K2319/35 ,  C07K2319/75 ,  C12N9/1033 ,  C12N15/62 ,  C12P21/06 ,  C12Y203/01028

摘要： A method is described for producing a peptide having a pI above 8 or below 5 wherein the peptide is expressed as a fusion protein in which it is linked to a fusion partner through an acid cleavage site. The peptide is released from the fusion partner by acid cleavage in the absence of chaotrope. The fusion partner and its acid cleavage products, if any, have a net charge sufficiently different from that of the desired peptide to allow isolation of the peptide by ion-exchange chromatography.

摘要翻译： 描述了一种制备pI高于8或低于5的肽的方法，其中肽被表达为通过酸切割位点与融合配偶体连接的融合蛋白。 在不存在离液剂的情况下，通过酸裂解将肽从融合伴侣释放出来。 融合配偶体及其酸裂解产物（如果有的话）具有与所需肽充分不同的净电荷，以允许通过离子交换层析分离肽。

公开(公告)号：EP1107959B1

公开(公告)日：2006-10-11

申请号：EP99949568.2

申请日：1999-08-27

申请人： SCIOS INC.

发明人： CHAKRAVARTY, Sarvajit ,  DUGAR, Sundeep ,  PERUMATTAM, John, J. ,  SCHREINER, George, F. ,  LIU, David, Y. ,  LEWICKI, John, A.

IPC分类号： C07D239/91 ,  C07D215/00 ,  C07D239/72 ,  A61P29/00 ,  A61K31/505 ,  A61K31/47

CPC分类号： C07D401/12 ,  A61K31/519 ,  C07D239/94 ,  C07D471/04

摘要： The invention is directed to methods to inhibit TGF-β and/or p38-α kinase using compounds of formula (1) or the pharmaceutically acceptable salts thereof wherein R3 is a noninterfering substituent; each Z is CR2 or N, wherein no more than two Z positions in ring A are N, and wherein two adjacent Z positions in ring A cannot be N; each R2 is independently a noninterfering substituent; L is a linker; n is 0 or 1; and Ar' is the residue of a cyclic aliphatic, cyclic heteroaliphatic, aromatic or heteroaromatic moiety optionally substituted with 1-3 noninterfering substituents.

公开(公告)号：EP1699767A2

公开(公告)日：2006-09-13

申请号：EP04816043.6

申请日：2004-12-31

申请人： Scios, Inc.

发明人： CHAKRAVARTY, Sarvajit ,  DUGAR, Sundeep ,  TESTER, Richland ,  CONTE, Aurelia

IPC分类号： C07D239/90 ,  C07D239/91 ,  C07D471/04

CPC分类号： C07D239/91 ,  C07D471/04

摘要： The present invention is directed to a rpocess for making 2-substituted pyridopyrimidones. In particular, 2-substituted pyridopyrimidones are made through the single step reaction of suitable acid derivatives with desired derivatives of amidines.

摘要翻译： 本发明涉及制备2-取代的吡啶并嘧啶酮的方法。 具体地说，2-取代的吡啶并嘧啶酮是通过合适的酸衍生物与期望的脒衍生物的单步反应制备的。

公开(公告)号：EP1669756A2

公开(公告)日：2006-06-14

申请号：EP05020597.0

申请日：2000-06-30

申请人： SCIOS INC.

发明人： Hyslop, Paul, Andrew ,  Miller, Foy, Dean ,  Higgins, Linda, S. ,  Catalano, Rosanne ,  Cordell, Barbara ,  Puchacz, Elzbieta

IPC分类号： G01N33/50 ,  A61P25/28 ,  G01N33/68

CPC分类号： G01N33/6896 ,  G01N33/5058 ,  G01N2333/4709 ,  G01N2800/2821

摘要： The present invention provides assays to identify compounds that affect microglial cell activation, and specifically assays to identify compounds that affect secretion of cytokines from these microglial cells by modulating PGE 2 -mediated activity. The assays of the invention include assays for testing microglial cell activation by contacting microglia with compounds that modulate β-amyloid PGE 2 -mediated activation, which can be identified by cellular activity such as secretion of cytokines, e.g., TNF-α and IL-1α. The effect of the candidate compound can be determined by comparing the effect with a control culture which is not contacted with the compound, or by comparing the effect with a standardized profile.

摘要翻译： 本发明提供了鉴定影响小胶质细胞活化的化合物的测定法，特别是通过调节PGE 2介导的活性来鉴定影响来自这些小神经胶质细胞的细胞因子分泌的化合物的测定法。 本发明的测定包括通过将小胶质细胞与调节β-淀粉样蛋白PGE 2介导的活化的化合物接触来测试小胶质细胞活化的测定法，其可以通过细胞活性如细胞因子分泌，例如TNF-α和IL-1 ±。 可以通过将效果与不与化合物接触的对照培养物进行比较，或通过将效果与标准化谱比较来确定候选化合物的效果。

公开(公告)号：EP1095141B1

公开(公告)日：2006-04-19

申请号：EP99932242.3

申请日：1999-07-08

申请人： SCIOS INC.

发明人： POLLITT, N., Stephen ,  BUCKLEY, Douglas, I. ,  STATHIS, Peter, A. ,  HARTMAN, Taymar, E. ,  ZHONG, Ziyang

IPC分类号： C12N15/12 ,  C12N15/62 ,  C07K1/18 ,  C07K1/12

CPC分类号： C07K1/36 ,  C07K1/122 ,  C07K14/58 ,  C07K2319/00 ,  C07K2319/35 ,  C07K2319/75 ,  C12N9/1033 ,  C12N15/62 ,  C12P21/06 ,  C12Y203/01028

摘要： A method is described for producing a peptide having a pI above 8 or below 5 wherein the peptide is expressed as a fusion protein in which it is linked to a fusion partner through an acid cleavage site. The peptide is released from the fusion partner by acid cleavage in the absence of chaotrope. The fusion partner and its acid cleavage products, if any, have a net charge sufficiently different from that of the desired peptide to allow isolation of the peptide by ion-exchange chromatography.

公开(公告)号：EP1575506A2

公开(公告)日：2005-09-21

申请号：EP03771821.0

申请日：2003-07-23

申请人： Scios, Inc.

发明人： LI, Zhihe ,  LIU, David, Y. ,  MA, Jing, Ying ,  PROTTER, Andrew ,  SCHREINER, George, F. ,  TRAN, Thomas-Toan

IPC分类号： A61K6/00

CPC分类号： A61K31/00 ,  A61K31/34 ,  A61K31/381 ,  A61K31/40 ,  A61K31/4035 ,  A61K31/498 ,  A61K31/4985 ,  A61K31/505 ,  A61K31/506 ,  A61K31/517 ,  A61K31/519 ,  A61K31/53 ,  A61K31/5355

摘要： The invention concerns methods for improvement of lung function by administering non-peptide small molecule inhibitors of TGF-β specifically binding to the type I TGF-β receptor (TGFβ-R1). Preferably, the inhibitors are quinazoline derivatives.